Sugary Kefir Strain Lactobacillus mali APS1 Ameliorated Hepatic Steatosis by Regulation of SIRT‐1/Nrf‐2 and Gut Microbiota in Rats
- 3 April 2018
- journal article
- research article
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 62 (8), e1700903
- https://doi.org/10.1002/mnfr.201700903
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a common disease that is concomitant with obesity, resulting in increased mortality. To date, the efficiency of NAFLD treatment still needs to be improved. Therefore, we aimed to evaluate the effect of Lactobacillus mali APS1, which was isolated from sugary kefir, on hepatic steatosis in rats fed a high-fat diet (HFD). Sprague Dawley rats were fed a control diet, a high-fat diet with saline and a high-fat diet with APS1 intervention by gavage daily for 12 weeks. The results showed that APS1 significantly reduced body weight and body weight gain in HFD-fed rats. APS1 reduced hepatic lipid accumulation by regulating SIRT-1/PGC-1α/SREBP-1 expression. Moreover, APS1 increased hepatic antioxidant activity by modulating Nrf-2/HO-1 expression. Notably, APS1 manipulated the gut microbiota, resulting in increasing proportions of the phylum Bacteroidetes/Firmicutes and reducing the abundance of specific NAFLD-associated bacteria. These results suggested that APS1 ameliorated hepatic steatosis by modulating lipid metabolism and antioxidant activity via manipulating specific NAFLD-associated gut microbiota in vivo. This article is protected by copyright. All rights reservedKeywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 104-2313-B-002-043-MY3)
This publication has 56 references indexed in Scilit:
- Butyrate-Producing Probiotics Reduce Nonalcoholic Fatty Liver Disease Progression in Rats: New Insight into the Probiotics for the Gut-Liver AxisPLOS ONE, 2013
- Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed ratsNutrition & Metabolism, 2013
- SIRT1 Deacetylates and Inhibits SREBP-1C Activity in Regulation of Hepatic Lipid Metabolism*Journal of Biological Chemistry, 2010
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathwayHepatology, 2010
- Hepatocyte-Specific Deletion of SIRT1 Alters Fatty Acid Metabolism and Results in Hepatic Steatosis and InflammationCell Metabolism, 2009
- AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activityNature, 2009
- Intracellular Lipid Accumulation in Liver and Muscle and the Insulin Resistance SyndromeEndocrinology and Metabolism Clinics of North America, 2008
- A core gut microbiome in obese and lean twinsNature, 2008
- Sirt1 protects against high-fat diet-induced metabolic damageProceedings of the National Academy of Sciences of the United States of America, 2008
- Molecular Fingerprinting of the Fecal Microbiota of Children Raised According to Different LifestylesApplied and Environmental Microbiology, 2007